Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)

Psoriatic Arthritis

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Res Ther

Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR

doi: 10.1186/s13075-024-03442-2

Further Publications Rheumatology

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Res Ther

Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A

doi: 10.1186/s13075-024-03412-8

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Further Publications Rheumatology

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

BMJ Open

Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Curtis P, Gupta A, Nijhawan R, O'Shea C, Rayner K, Saurigny D, Shelton C, Wang M, Wang R, Fleischmann RM

doi: 10.1136/bmjopen-2024-088869

PsoriasisPsoriatic Arthritis

Long-term Cardiovascular Safety of Ustekinumab in Psoriasis and Psoriatic Arthritis: Results from an Observational Post-Authorization Safety Study Based on Swedish National Registers

J Am Acad Dermatol

Banefelt J, Skröder H, Azzabi A, Sheahan A, Suruki R, Geldhof A

doi: 10.1016/j.jaad.2025.03.016

Autoimmune Disease

Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis

Rheumatology (Oxford)

Wang Z, Lu Y, Qiu X, Xu Y, Xu X, Guo L, Zheng Q, Zou L, Xu X, Lu M

doi: 10.1093/rheumatology/keaf225

Further Publications Dermatology

Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the Phase III EASE Study

Br J Dermatol

Murrell DF, Bodemer C, Bruckner AL, Cunningham T, Davis C, Fernández MF, Kiritsi D, Maher L, Sprecher E, Torres Pradilla M, Kern JS

doi: 10.1093/bjd/ljaf022

Alopecia Areata

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Br J Dermatol

Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, Magnolo N, Piraccini BM, Luo X, Wolk R, Woodworth D, Schaefer G, Lejeune A

doi: 10.1093/bjd/ljae365

Further Publications Rheumatology

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology (Oxford)

Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Vaux T, Prajapati C, Manente M, Marten A, Gensler LS

doi: 10.1093/rheumatology/keaf009

Related content

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Long-term Cardiovascular Safety of Ustekinumab in Psoriasis and Psoriatic Arthritis: Results from an Observational Post-Authorization Safety Study Based on Swedish National Registers

Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis

Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the Phase III EASE Study

Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies